Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001867096-25-000013
Filing Date
2025-01-07
Accepted
2025-01-07 16:42:30
Documents
1
Period of Report
2025-01-03

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1736286143.html 4  
1 FORM 4 wk-form4_1736286143.xml 4 3670
  Complete submission text file 0001867096-25-000013.txt   5127
Mailing Address C/O XERIS PHARMACEUTICALS, INC. 180 N. LASALLE STREET, SUITE 1800 CHICAGO IL 60601
Business Address
JOHNSON KENNETH ERLAND (Reporting) CIK: 0001743774 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-40880 | Film No.: 25515379

Mailing Address 1375 WEST FULTON STREET, SUITE 1300 CHICAGO IL 60607
Business Address 1375 WEST FULTON STREET, SUITE 1300 CHICAGO IL 60607 844-445-5704
Xeris Biopharma Holdings, Inc. (Issuer) CIK: 0001867096 (see all company filings)

EIN.: 871082097 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)